These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 17695089)
1. Report from the XVI International HIV Drug Resistance Workshop. Kuritzkes DR AIDS Clin Care; 2007 Aug; 19(8):69-70. PubMed ID: 17695089 [No Abstract] [Full Text] [Related]
2. [New antiretroviral drug classes in HIV therapy]. Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081 [No Abstract] [Full Text] [Related]
3. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. Stephenson J JAMA; 2007 Apr; 297(14):1535-6. PubMed ID: 17426263 [No Abstract] [Full Text] [Related]
4. Two new drugs for HIV infection. Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163 [No Abstract] [Full Text] [Related]
5. Pivotal moments in HIV treatment: the 14th CROI. Laurence J AIDS Read; 2007 May; 17(5):239-40. PubMed ID: 17532657 [No Abstract] [Full Text] [Related]
6. Anti-HIV agents. New drugs--hope and a degree of caution. TreatmentUpdate; 2007; 19(6):9-10. PubMed ID: 18041153 [No Abstract] [Full Text] [Related]
8. New HIV drug classes on the horizon. Opar A Nat Rev Drug Discov; 2007 Apr; 6(4):258-9. PubMed ID: 17457997 [No Abstract] [Full Text] [Related]
9. Advances in HIV therapeutics: the 14th CROI. Boyle BA; Elion R; Cohen CJ; Moyle GJ; Sax P; Frank I AIDS Read; 2007 May; 17(5):268-70, 272-4, 283-6. PubMed ID: 17532664 [No Abstract] [Full Text] [Related]
10. HIV treatment and the nonclinician: getting your bearings. HRSA Careaction; 2007 Jan; ():1-12. PubMed ID: 17380596 [No Abstract] [Full Text] [Related]
11. When and how to use maraviroc in HIV-infected patients. Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318 [No Abstract] [Full Text] [Related]
12. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances]. MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918 [No Abstract] [Full Text] [Related]
13. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. Delobel P; Raymond S; Mavigner M; Cazabat M; Alvarez M; Marchou B; Massip P; Izopet J AIDS; 2010 Jun; 24(9):1382-4. PubMed ID: 20559045 [No Abstract] [Full Text] [Related]
14. HIV entry inhibitors: progress in development and application. Lai WH; Huang L; Chen CH Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414 [TBL] [Abstract][Full Text] [Related]
15. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge. Horster S; Goebel FD Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305 [No Abstract] [Full Text] [Related]
17. A new class of anti-HIV therapy and new challenges. Dolin R N Engl J Med; 2008 Oct; 359(14):1509-11. PubMed ID: 18832250 [No Abstract] [Full Text] [Related]